Show simple item record

dc.contributor.authorBroadley, S
dc.contributor.authorSinger, BA
dc.contributor.authorAlroughani, R
dc.contributor.authorEichau, S
dc.contributor.authorHartung, H-P
dc.contributor.authorHavrdova, EK
dc.contributor.authorKim, HJ
dc.contributor.authorNakamura, K
dc.contributor.authorNavas, C
dc.contributor.authorPozzilli, C
dc.contributor.authorRovira, A
dc.contributor.authorVermersch, P
dc.contributor.authorWray, S
dc.contributor.authorChung, L
dc.contributor.authoret al.
dc.description.abstractBackground: In CARE-MS II (NCT00548405), 2 alemtuzumab courses (12 mg/day; baseline: 5 days; 12 months [M] later: 3 days) significantly improved clinical/MRI outcomes versus SC IFNB-1a over 2 years (y) in RRMS patients with inadequate response to prior therapy. Efficacy was maintained in a 4-y extension (NCT00930553), wherein patients could receive additional alemtuzumab (12 mg/day; 3 days; ⩾12M apart) as needed for disease activity or other disease-modifying therapy (DMT). Patients could continue in an additional 5-y extension (TOPAZ; NCT02255656). Aims: To evaluate 8-y efficacy/safety of alemtuzumab in CARE-MS II patients. Methods: At investigator’s discretion, patients in TOPAZ can receive as-needed additional alemtuzumab (⩾12M apart; no criteria) or other DMT (any time). Results: 300/435 (69%) patients completed TOPAZ Y2 (Y8 after initiating alemtuzumab); 44% received neither additional alemtuzumab nor another DMT. At Y8, annualised relapse rate was 0.18, 85% were relapse-free, 70% had stable/improved EDSS versus baseline, and mean EDSS change was 0.17. Through Y8, 64% were free of 6-month confirmed disability worsening, and 47% achieved 6-month confirmed disability improvement. In Y8, 58% achieved no evidence of disease activity, and 70% were free of MRI disease activity. Median percent brain volume loss (BVL) from baseline through Y8 was –1.06%; BVL was –0.19% or less annually in Y3–8. Safety remained consistent through Y8, with no new immune thrombocytopenia or nephropathy cases. Conclusion: Efficacy of alemtuzumab on clinical, MRI, and BVL outcomes was maintained through Y8 in absence of continuous treatment in CARE-MS II patients, with a consistent and manageable safety profile.
dc.publisherSage Publications Ltd
dc.relation.ispartofconferencenameCongress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS)
dc.relation.ispartofconferencetitleMultiple Sclerosis Journal
dc.relation.ispartoflocationSydney, Australia
dc.subject.fieldofresearchClinical Sciences
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsClinical Neurology
dc.subject.keywordsNeurosciences & Neurology
dc.titleAlemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS II Follow-up (TOPAZ Study)
dc.typeConference output
dc.type.descriptionE3 - Conferences (Extract Paper)
dcterms.bibliographicCitationBroadley, S; Singer, BA; Alroughani, R; Eichau, S; Hartung, H-P; Havrdova, EK; Kim, HJ; Nakamura, K; Navas, C; Pozzilli, C; Rovira, A; Vermersch, P; Wray, S; Chung, L; et al., Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS II Follow-up (TOPAZ Study), Multiple Sclerosis Journal, 2019, 25 (3), pp. 462-462
gro.hasfulltextNo Full Text
gro.griffith.authorBroadley, Simon

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record